{
  "id": 4851272,
  "title": "Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)",
  "url": "https://urgent.news/2026/09/01/stoke-therapeutics-and-biogen-announce-presentations-of-clinical-data",
  "topic": "world",
  "section": "World",
  "published": "2026-09-01T11:33:52.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/stoke-therapeutics-and-biogen-announce-presentations-of-clinical-data-from-studies-of-zorevunersen-an-investigational-medicine-for-the-treatment-of-dravet-syndrome-at-the-16th-european-epilepsy-cong"
  },
  "original_language": "en",
  "account": null,
  "summary": "–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen– –Improvements in cognition and behavior sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile– –New data from sub-analyses of patients treated with zorevunersen in the Phase 1/2a OLEs include effects on […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}